Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

25 Jun 2013

Abstract excerpt

Rearrangements of the MLL gene define a genetically distinct subset of acute leukemias with poor prognosis. Current treatment options are of limited effectiveness; thus, there is a pressing need for new therapies for this disease. Genetic and small molecule inhibitor studies have demonstrated that the histone methyltransferase DOT1L is required for the development and maintenance of MLL-rearranged leukemia in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer-related gene regulation
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23801631
DOI: 10.1182/blood-2013-04-497644

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potent inhibition of DOT1L as treatment of MLL-fusion leukemiaPMID 23801631Read ↗

MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibitionSemantic proximity Read ↗

DOT1L Inhibition Sensitizes MLL-Rearranged AML to ChemotherapySemantic proximity Read ↗

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenograftsSemantic proximity Read ↗

Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute LeukemiaSemantic proximity Read ↗

Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein–Protein Interactions between DOT1L and MLL-AF9/MLL-ENLSemantic proximity Read ↗

DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.Semantic proximity Read ↗

DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.Semantic proximity Read ↗

Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL -Rearranged LeukemiaSemantic proximity Read ↗

Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological InterventionsSemantic proximity Read ↗

Histone H3 Lysine 79 Methyltransferase Dot1 Is Required for Immortalization by MLL OncogenesSemantic proximity Read ↗

Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapySemantic proximity Read ↗

Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1lSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.